SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.

ABSTRACT: SLC26A9 belongs to the solute carrier family 26 (SLC26), which comprises membrane proteins involved in ion transport mechanisms. On the basis of different preliminary findings, including the phenotype of SlC26A9-deficient mice and its possible role as a gene modifier of the human phenotype and treatment response, SLC26A9 has emerged as one of the most interesting alternative targets for the treatment of cystic fibrosis (CF). However, despite relevant clues, some open issues and controversies remain. The lack of specific pharmacological modulators, the elusive expression reported in the airways, and its complex relationships with CFTR and the CF phenotype prevent us from conclusively understanding the contribution of SLC26A9 in human lung physiology and its real potential as a therapeutic t

SUBMITTER: Gorrieri G 

PROVIDER: S-EPMC8961553 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature